Affinity Asset Advisors LLC Purchases 908,483 Shares of Compass Pathways PLC Sponsored ADR $CMPS

Affinity Asset Advisors LLC lifted its holdings in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 454.2% in the first quarter, HoldingsChannel.com reports. The fund owned 1,108,483 shares of the company’s stock after acquiring an additional 908,483 shares during the period. Affinity Asset Advisors LLC’s holdings in Compass Pathways were worth $6,130,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Persistent Asset Partners Ltd purchased a new position in Compass Pathways in the fourth quarter worth $38,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Compass Pathways during the 4th quarter valued at $47,000. Advisory Services Network LLC bought a new stake in shares of Compass Pathways during the 3rd quarter worth $41,000. Parallel Advisors LLC raised its stake in shares of Compass Pathways by 8,450.6% during the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock worth $40,000 after purchasing an additional 7,183 shares during the period. Finally, North Star Investment Management Corp. boosted its holdings in shares of Compass Pathways by 1,354.0% in the 1st quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock worth $42,000 after buying an additional 7,000 shares during the last quarter. 46.19% of the stock is currently owned by institutional investors.

Compass Pathways Trading Down 3.8%

Shares of Compass Pathways stock opened at $11.26 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.32 and a quick ratio of 3.32. Compass Pathways PLC Sponsored ADR has a 1 year low of $3.92 and a 1 year high of $15.40. The firm has a market cap of $1.52 billion, a PE ratio of -3.57 and a beta of 2.47. The company has a 50 day simple moving average of $12.51 and a two-hundred day simple moving average of $9.01.

Compass Pathways (NASDAQ:CMPS) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.15. Analysts expect that Compass Pathways PLC Sponsored ADR will post -1.24 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on CMPS shares. Stifel Nicolaus lifted their price objective on shares of Compass Pathways from $14.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Canaccord Genuity Group upped their price objective on Compass Pathways from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Friday, June 26th. Oppenheimer reissued an “outperform” rating and set a $20.00 price objective on shares of Compass Pathways in a report on Tuesday, July 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Pathways in a research report on Friday, July 17th. Finally, Compass Point set a $25.00 target price on Compass Pathways in a research note on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $24.15.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.